| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/29/2010 | CN101209256B Polydatin medicinal composition containing polyvinyl pyrrolidone |
| 09/29/2010 | CN101181478B Chinese medicine for curing lung cancer and mammary cancer |
| 09/29/2010 | CN101177453B Recombined chimeric antibody against human tumor necrosis factor alpha |
| 09/29/2010 | CN101175495B Anti-cancer compound combination |
| 09/29/2010 | CN101125837B C-glycosides type slycolipid compounds and use thereof |
| 09/29/2010 | CN101074227B Phosphine acyloxy quinazoline derivatives and their medicine uses |
| 09/29/2010 | CN101062240B Traditional Chinese medicine preparation for treating leukocythemia |
| 09/29/2010 | CN101049336B New composition of medication for anti cancer |
| 09/29/2010 | CN101045073B Method for preparing extractive of liuyueqing and its application |
| 09/28/2010 | USRE41783 Pyrrolo[2,3-D]pyrimidine compounds |
| 09/28/2010 | US7803956 (2,4-Dichloro-phenyl)-(3-methyl-6-m-tolyl-benzofuran-2-yl)-methanone; anticarcinogenic, antiproliferative, antitumor agent; solid tumor, metastasis, lymphomas, leukemia; Cell Titre-Glo/High Throughput Assay |
| 09/28/2010 | US7803945 Tetrahydropyridothiophenes |
| 09/28/2010 | US7803903 Protein-binding doxorubicin peptide derivatives |
| 09/28/2010 | US7803823 having proinflammatory cytokine production inhibiting properties, in particular tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-12 (IL-12) inhibiting properties, used for the prevention or the treatment of inflammatory and/or autoimmune diseases |
| 09/28/2010 | US7803811 1-methoxy-2-methyl-3-[(4-nitrophenyl)sulphonyl]indolizine, used as angiogenesis inhibitors |
| 09/28/2010 | US7803806 protein kinase inhibitors such as 1-{3-[4-(5-Bromo-thiophen-2-yl)-pyrimidin-2-ylamino]-phenyl}-ethanol, used for the treatment of breast cancer or rheumatoid arthritis |
| 09/28/2010 | US7803805 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents |
| 09/28/2010 | US7803800 Histone deacetylases inhibitors |
| 09/28/2010 | US7803795 and nitric oxide synthase inhibitor; e.g. 1-(phenylmethyl)-4-piperidyl-6-phthalazine-3one; antiinflammatory agent; preserve the cellular energy level: survival of ischaemic tissues after insult; neurodegenerative diseases: stroke, Alzheimer's and Parkinson's diseases, atherosclerosis, osteoarthritis |
| 09/28/2010 | US7803791 biological conjugate drug comprising enzyme inhibitor antibiotics and protein, for the treatment and/or prophylaxis of bacterial inflammatory processes, solid tumor; norfloxacin with albumin; antiinflammatory agents, antitumor agents |
| 09/28/2010 | US7803788 Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability |
| 09/28/2010 | US7803776 Combined use of enzyme inhibitors and of pharmaceutical compositions thereof |
| 09/28/2010 | US7803772 Administering a polypeptide having at least one of anti-angiogenic, tumor-suppressive, or anti-migratory activity, but does not have stimulation of cell proliferation activity |
| 09/28/2010 | US7803757 For treatment of urinary tract infections and inflammations, colitis, and candida infections of mucosal membranes; infant formula food containing the peptide |
| 09/28/2010 | US7803618 nucleic acid encoding an anti-EpCAM protein; binds human epithelial cell adhesion molecule; immunoglobulin light chain region modified to reduce immunogenicity; diagnosis, prognosis and treatment of cancer |
| 09/28/2010 | US7803615 Death domain containing receptor 5 |
| 09/28/2010 | US7803614 isolated host cell transfected with the recombinant expression vector encoding an immunogenic protein; diagnosis of skin cancer; vaccine for prevent and treatment; immunotherapy |
| 09/28/2010 | US7803600 inhibitors of vacuolar-type H+-ATPase; antibiotic; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16- [(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one |
| 09/28/2010 | US7803595 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 09/28/2010 | US7803560 Contacting a candidate antagonist with a MCP-1 receptor polypeptide having an amino acid sequence at least 95% homologous to an extracellular domain of a specific sequence, and comparing the binding of MCP-1 to the receptor polypeptide; decreased binding indicates an antagonist |
| 09/28/2010 | US7803546 Method of screening for sensitivity to kinase inhibitor therapy |
| 09/28/2010 | US7803399 Delivery system for nucleic acids |
| 09/28/2010 | US7803381 Synthetic peptide comprising the amino acid sequence GPRLGYSWHX in which each of the amino acids are in the D-amino acid configuration and X is any amino acid; optionally conjugated to the natural gonadotropin-releasing hormone peptide; vaccines for use incontrolling fertility or heat in an animal |
| 09/28/2010 | US7803379 Tumour-specific animal proteins |
| 09/28/2010 | US7803377 Anti-DLL4 antibodies and methods using same |
| 09/28/2010 | US7803361 Decreasing solid tumor size in a cancer patient by administering an interleukin-2 mutant with reduced vasopermeability activity compared to a wildtype form, and being Arg38Trp, wherein said wildtype form is human IL-2 mutant and the IL-2 mutant is not linked to an antibody. |
| 09/28/2010 | US7803350 Radioactive arsenic-containing compounds and their uses in the treatment of tumors |
| 09/28/2010 | CA2577441C Improved photosensitizer formulations and their use |
| 09/28/2010 | CA2481707C Benzopyran derivatives substituted with secondary amines having tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 09/28/2010 | CA2464758C Combination therapy comprising zd6474 and a taxane |
| 09/28/2010 | CA2464152C Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 09/28/2010 | CA2453881C 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives |
| 09/28/2010 | CA2395772C Sulfonamide-containing heterocyclic compounds |
| 09/28/2010 | CA2386417C Phenyl- and pyridyl-tetrahydropyridines having tnf-inhibiting activity |
| 09/28/2010 | CA2383257C Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 09/28/2010 | CA2382631C Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| 09/28/2010 | CA2376304C Amide substituted imidazoquinolines |
| 09/28/2010 | CA2286288C Monoclonal antibody recognizing the n-glycolylated-galacotose-glucose sialic acid oligosaccharide in malignant tumors and composition that contains it |
| 09/24/2010 | CA2719523A1 Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof |
| 09/23/2010 | WO2010108125A2 Psma-targeting compounds and uses thereof |
| 09/23/2010 | WO2010107968A1 Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| 09/23/2010 | WO2010107909A2 Methods and compositions for the detection of cancer |
| 09/23/2010 | WO2010107658A2 Methods and compositions for bi-specific targeting of cd19/cd22 |
| 09/23/2010 | WO2010107443A1 Renal cell carcinoma biomarkers |
| 09/23/2010 | WO2010107397A1 Modulators of apoptosis and the uses thereof |
| 09/23/2010 | WO2010107251A2 Pharmaceutical composition used in prophylaxis or treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient |
| 09/23/2010 | WO2010107116A1 Hla-a24-binding cancer antigen peptide derived from sox2 |
| 09/23/2010 | WO2010107083A1 Proliferation promoter for antigen-specific t cell |
| 09/23/2010 | WO2010106812A1 Pharmaceutical formulation containing improved antibody molecules |
| 09/23/2010 | WO2010106770A1 Neil3 peptides and vaccines including the same |
| 09/23/2010 | WO2010106494A1 Use of pharmaceutical compositions containing mesembrenone |
| 09/23/2010 | WO2010106366A1 Fk506 and fk520 analogues and their pharmaceutical uses |
| 09/23/2010 | WO2010106341A1 Compounds and biological materials and uses thereof |
| 09/23/2010 | WO2010106333A1 Compounds |
| 09/23/2010 | WO2010106290A1 Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof |
| 09/23/2010 | WO2010106135A1 Combined use for the treatment of ovarian carcinoma |
| 09/23/2010 | WO2010106097A1 Substituted pyrimidines for the treatment of cancer |
| 09/23/2010 | WO2010106028A1 Use of a kinase inhibitor for the treatment of thymoma |
| 09/23/2010 | WO2010105691A1 Gold (iii) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents |
| 09/23/2010 | WO2010105685A1 Peptides for inhibiting igf-1 |
| 09/23/2010 | WO2010105573A1 Anti-angiogenic fusion proteins |
| 09/23/2010 | WO2010105347A1 Vaccination methods |
| 09/23/2010 | WO2010105290A1 Humanised antibodies with anti-tumour activity |
| 09/23/2010 | WO2010084496A3 Fruit and vegetable-derived compositions |
| 09/23/2010 | WO2010073011A3 Heterocyclic compounds and their use as ampk activators |
| 09/23/2010 | WO2010065563A3 Apratoxin therapeutic agents: mechanism and methods of treatment |
| 09/23/2010 | WO2010062143A3 Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression |
| 09/23/2010 | WO2010059575A3 Combination therapy for the treatment of cancer |
| 09/23/2010 | WO2010042933A3 Inhibition and treatment of prostate cancer metastasis |
| 09/23/2010 | WO2010036959A3 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| 09/23/2010 | WO2010033425A3 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| 09/23/2010 | WO2010033424A3 Nutritional support of the immune system during anti-cancer treatment |
| 09/23/2010 | WO2010025872A3 Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl |
| 09/23/2010 | WO2010009155A3 Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| 09/23/2010 | WO2009134718A8 Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc |
| 09/23/2010 | WO2009098690A8 Novel fer -like protein, pharmaceutical compositions containing it and method for its use |
| 09/23/2010 | US20100240893 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 09/23/2010 | US20100240770 Synthesis and use of colloidal III-V nanoparticles |
| 09/23/2010 | US20100240751 Methods |
| 09/23/2010 | US20100240748 Tetrahydronaphthalen-2-ol derivatives |
| 09/23/2010 | US20100240747 Motuporamine Mimic Agents |
| 09/23/2010 | US20100240746 Stereoisomers of tricyclodecan-9-yl-xanthogenate |
| 09/23/2010 | US20100240742 Anti-angiogenic compositions and methods of use |
| 09/23/2010 | US20100240739 Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
| 09/23/2010 | US20100240738 Antisense modulation of kinesin-like 1 expression |
| 09/23/2010 | US20100240734 Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| 09/23/2010 | US20100240732 Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function |
| 09/23/2010 | US20100240731 Lipopeptides for delivery of nucleic acids |
| 09/23/2010 | US20100240724 Edible Film |
| 09/23/2010 | US20100240723 Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule |